JP2015517502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517502A5 JP2015517502A5 JP2015511789A JP2015511789A JP2015517502A5 JP 2015517502 A5 JP2015517502 A5 JP 2015517502A5 JP 2015511789 A JP2015511789 A JP 2015511789A JP 2015511789 A JP2015511789 A JP 2015511789A JP 2015517502 A5 JP2015517502 A5 JP 2015517502A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- fragment
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010056102 CD100 antigen Proteins 0.000 claims description 20
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 14
- 208000015114 central nervous system disease Diseases 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims description 2
- 102100034384 Plexin-B1 Human genes 0.000 claims description 2
- 101710100559 Plexin-B1 Proteins 0.000 claims description 2
- 102100034383 Plexin-B2 Human genes 0.000 claims description 2
- 101710100551 Plexin-B2 Proteins 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 206010008129 cerebral palsy Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- 210000005155 neural progenitor cell Anatomy 0.000 claims 2
- 102000008730 Nestin Human genes 0.000 claims 1
- 108010088225 Nestin Proteins 0.000 claims 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 210000005055 nestin Anatomy 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261646119P | 2012-05-11 | 2012-05-11 | |
| US61/646,119 | 2012-05-11 | ||
| US13/842,523 US10494440B2 (en) | 2012-05-11 | 2013-03-15 | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| US13/842,523 | 2013-03-15 | ||
| PCT/US2013/040661 WO2013170221A1 (en) | 2012-05-11 | 2013-05-10 | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517502A JP2015517502A (ja) | 2015-06-22 |
| JP2015517502A5 true JP2015517502A5 (enExample) | 2016-07-07 |
| JP6218810B2 JP6218810B2 (ja) | 2017-10-25 |
Family
ID=49548777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511789A Active JP6218810B2 (ja) | 2012-05-11 | 2013-05-10 | 卒中後の神経形成を促進するためのセマフォリン−４ｄ結合分子の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10494440B2 (enExample) |
| EP (1) | EP2846831B1 (enExample) |
| JP (1) | JP6218810B2 (enExample) |
| KR (1) | KR102105436B1 (enExample) |
| CN (2) | CN110064054A (enExample) |
| AU (1) | AU2013259192B2 (enExample) |
| BR (1) | BR112014028160B1 (enExample) |
| CA (1) | CA2872928C (enExample) |
| DK (1) | DK2846831T3 (enExample) |
| EA (1) | EA030796B1 (enExample) |
| ES (1) | ES2882881T3 (enExample) |
| IL (1) | IL235603B (enExample) |
| MX (1) | MX358991B (enExample) |
| NZ (1) | NZ630864A (enExample) |
| PT (1) | PT2846831T (enExample) |
| SG (1) | SG11201407416XA (enExample) |
| WO (1) | WO2013170221A1 (enExample) |
| ZA (1) | ZA201501674B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| BR112018071686A2 (pt) | 2016-04-22 | 2019-02-19 | Vaccinex, Inc. | exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| WO2018156509A1 (en) * | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| CN110636858B (zh) | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
| WO2024182357A1 (en) * | 2023-02-28 | 2024-09-06 | Brandeis University | Compositions and methods for the chronic treatment of epilepsy and epileptogenesis |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| AU776865B2 (en) | 1998-11-10 | 2004-09-23 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| WO2001046384A2 (en) | 1999-12-23 | 2001-06-28 | Cornell Research Foundation, Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| RU2006124743A (ru) | 2003-12-11 | 2008-01-20 | Дженентек, Инк. (Us) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет |
| AU2005209331A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| JP2008504821A (ja) * | 2004-07-01 | 2008-02-21 | バイレクシス コーポレイション | ベクター・パッケージング細胞系列 |
| US7476724B2 (en) | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| EP1871484A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Sema4d in cancer diagnosis, detection and treatment |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| EP2069404B1 (en) | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| WO2009089461A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
| CN102421913A (zh) * | 2009-03-13 | 2012-04-18 | 宾夕法尼亚大学董事会 | Ox40/trail融合蛋白 |
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| US8834883B2 (en) | 2010-06-14 | 2014-09-16 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| US9447191B2 (en) | 2011-05-13 | 2016-09-20 | National University Corporation Tokyo Medical And Dental University | Osteogenesis promoter |
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| WO2018156509A1 (en) * | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
-
2013
- 2013-03-15 US US13/842,523 patent/US10494440B2/en active Active
- 2013-05-10 BR BR112014028160-2A patent/BR112014028160B1/pt active IP Right Grant
- 2013-05-10 JP JP2015511789A patent/JP6218810B2/ja active Active
- 2013-05-10 MX MX2014013676A patent/MX358991B/es active IP Right Grant
- 2013-05-10 CN CN201910064594.5A patent/CN110064054A/zh active Pending
- 2013-05-10 EA EA201492067A patent/EA030796B1/ru not_active IP Right Cessation
- 2013-05-10 CA CA2872928A patent/CA2872928C/en active Active
- 2013-05-10 ES ES13787931T patent/ES2882881T3/es active Active
- 2013-05-10 AU AU2013259192A patent/AU2013259192B2/en not_active Ceased
- 2013-05-10 WO PCT/US2013/040661 patent/WO2013170221A1/en not_active Ceased
- 2013-05-10 DK DK13787931.8T patent/DK2846831T3/da active
- 2013-05-10 PT PT137879318T patent/PT2846831T/pt unknown
- 2013-05-10 KR KR1020147034510A patent/KR102105436B1/ko active Active
- 2013-05-10 NZ NZ630864A patent/NZ630864A/en not_active IP Right Cessation
- 2013-05-10 EP EP13787931.8A patent/EP2846831B1/en active Active
- 2013-05-10 CN CN201380037262.9A patent/CN104619341A/zh active Pending
- 2013-05-10 SG SG11201407416XA patent/SG11201407416XA/en unknown
-
2014
- 2014-11-10 IL IL235603A patent/IL235603B/en active IP Right Grant
-
2015
- 2015-03-11 ZA ZA2015/01674A patent/ZA201501674B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517502A5 (enExample) | ||
| JP2019527194A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| AU2024201029A1 (en) | Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof | |
| JP2018517401A5 (enExample) | ||
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| JP2016539096A5 (enExample) | ||
| JP2018521691A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2009545325A5 (enExample) | ||
| JP2009525764A5 (enExample) | ||
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| TW201920263A (zh) | 檢查點抑制劑雙特異性抗體 | |
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| JP2016505556A5 (enExample) | ||
| JP2014530239A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2017500018A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| JP2015533795A5 (enExample) | ||
| JP2018503380A5 (enExample) | ||
| JP2018510617A5 (enExample) |